Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction | Zendy

Akio Kawakami | Zendy; Mizuko Osaka | Zendy; Mariko Tani | Zendy; Hiroshi Azuma | Zendy; Frank M. Sacks | Zendy; Kentaro Shimokado | Zendy; Masayuki Yoshida | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction

Author(s) -

Akio Kawakami,

Mizuko Osaka,

Mariko Tani,

Hiroshi Azuma,

Frank M. Sacks,

Kentaro Shimokado,

Masayuki Yoshida

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.784785

Subject(s) - medicine , endocrinology , endothelial dysfunction , insulin receptor , enos , protein kinase b , endothelium , protein kinase c , signal transduction , insulin , biology , insulin resistance , microbiology and biotechnology , nitric oxide synthase , nitric oxide

Apolipoprotein CIII (apoCIII) is a component of some triglyceride-rich very-low-density and low-density lipoprotein and is elevated in dyslipidemia with insulin resistance and the metabolic syndrome. We previously reported that apoCIII directly activates proinflammatory and atherogenic signaling in vascular endothelial cells through protein kinase C-beta (PKCbeta). Because PKCbeta impairs the response of vascular endothelial cells to insulin, we tested the hypothesis that apoCIII affects insulin signaling in vascular endothelial cells and its function in vitro and in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research